Table 3 Comparison of grade ≥ 3 side effects between boost modalities

Skin

 1. Acute

28 (25.5)

29 (21.8)

0.742

57 (23.5)

 2. Late

5 (4.5)

5 (3.8)

10 (4.1)

 3. None

77 (70.0)

99 (74.4)

176 (72.4)

Osteoradionecrosis

 2. Late

9 (8.2)

11 (8.3)

1.000

20 (8.2)

 3. None

101 (91.8)

122 (91.7)

223 (91.8)

Larynx

 1. Acute

0 (0.0)

0 (0.0)

1.000

0 (0.0)

 2. Late

1 (0.9)

2 (1.5)

3 (1.2)

 3. None

109 (99.1)

131 (98.5)

240 (98.8)

Salivary glands

 2. Late

8 (7.3)

9 (6.8)

1.000

17 (7.0)

 3. None

102 (92.7)

124 (93.2)

226 (93.0)

Trismus

 1. Acute

1 (0.9)

0 (0.0)

0.545

1 (0.4)

 2. Late

4 (3.6)

5 (3.8)

9 (3.7)

 3. None

105 (95.5)

128 (96.2)

233 (95.9)

Mucosa

 1. Acute

71 (64.5)

83 (62.4)

0.817

154 (63.4)

 2. Late

2 (1.8)

4 (3.0)

6 (2.5)

 3. None

37 (33.6)

46 (34.6)

83 (34.2)

Dysphagia

 2. Late

16 (14.5)

24 (18.0)

0.577

40 (16.5)

 3. None

94 (85.5)

109 (82.0)

203 (83.5)